Literature DB >> 7981018

Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.

P C Waller1, S M Wood, A M Breckenridge, M D Rawlins.   

Abstract

Mesh：

Year:  1994        PMID： 7981018      PMCID： PMC1364851          DOI： 10.1111/j.1365-2125.1994.tb04329.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  New horizons in post-marketing surveillance.

Authors:  P Waller; S Wood
Journal:  Health Trends       Date:  1993

2.  Review of company postmarketing surveillance studies.

Authors:  P C Waller; S M Wood; M J Langman; A M Breckenridge; M D Rawlins
Journal:  BMJ       Date:  1992-06-06
  2 in total
  2 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 2.  Good practice in the postmarketing surveillance of medicines.

Authors:  R H Meyboom
Journal:  Pharm World Sci       Date:  1997-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.